Literature DB >> 3028561

[3H]-verapamil binding to rat cardiac sarcolemmal membrane fragments; an effect of ischaemia.

J S Dillon, W G Nayler.   

Abstract

The [3H]-verapamil binding activity of rat cardiac sarcolemmal fragments was studied, using membranes harvested from non-perfused, aerobically-perfused and ischaemic hearts. Glass-fibre filters were found to contain specific, high affinity--(KD 38 +/- 3.1 nM) [3H]-verapamil binding sites--making them unsuitable for use in [3H]-verapamil binding studies. Incubation of membranes from non-perfused hearts in a medium containing 150 mM NaCl, 1 mM CaCl2 and 50 mM Tris revealed two populations of [3H]-verapamil binding sites. When centrifugation instead of filtration was used to separate bound and free [3H]-verapamil, high affinity sites with a KD of 0.57 +/- 0.19 microM and a Bmax of 38 +/- 5.2 pmol mg-1 protein, and low affinity sites with a KD of 78 +/- 27.5 microM and a Bmax of 2.9 +/- 1.3 nmol mg-1 protein were detected. However, only low affinity binding sites could be detected in membranes which had been incubated in a cation-free medium containing 50 mM Tris. [3H]-verapamil binding to the low and high affinity sites was saturable, reversible, stereospecific and displaceable by D600 greater than diltiazem greater than Ca2+ but not by nifedipine, nitrendipine, nisoldipine or prazosin. The two populations of binding sites survived aerobic perfusion and 60 min ischaemia at 37 degrees C. Ischaemia reduced the Bmax and KD but selectivity was maintained.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3028561      PMCID: PMC1917274          DOI: 10.1111/j.1476-5381.1987.tb16829.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  43 in total

1.  Ca2+ antagonist receptor sites on human red blood cell membranes.

Authors:  J Striessnig; G Zernig; H Glossmann
Journal:  Eur J Pharmacol       Date:  1985-02-05       Impact factor: 4.432

2.  Characterization of verapamil binding sites in cardiac membrane vesicles.

Authors:  M L Garcia; M J Trumble; J P Reuben; G J Kaczorowski
Journal:  J Biol Chem       Date:  1984-12-25       Impact factor: 5.157

Review 3.  Cellular action of calcium channel blocking drugs.

Authors:  A Schwartz; D J Triggle
Journal:  Annu Rev Med       Date:  1984       Impact factor: 13.739

4.  A practical computer-based approach to the analysis of radioligand binding experiments.

Authors:  G A McPherson
Journal:  Comput Programs Biomed       Date:  1983 Aug-Oct

5.  Molecular pharmacology of the calcium channel: evidence for subtypes, multiple drug-receptor sites, channel subunits, and the development of a radioiodinated 1,4-dihydropyridine calcium channel label, [125I]iodipine.

Authors:  H Glossmann; D R Ferry; A Goll; M Rombusch
Journal:  J Cardiovasc Pharmacol       Date:  1984       Impact factor: 3.105

6.  Sarcolemmal enzymes and Na+ -Ca2+ exchange in hypoxic, ischemic, and reperfused rat hearts.

Authors:  M J Daly; J S Elz; W G Nayler
Journal:  Am J Physiol       Date:  1984-08

7.  An effect of ischemia on myocardial dihydropyridine binding sites.

Authors:  W G Nayler; J S Dillon; J S Elz; M McKelvie
Journal:  Eur J Pharmacol       Date:  1985-09-10       Impact factor: 4.432

8.  [3H] verapamil binding sites in skeletal muscle transverse tubule membranes.

Authors:  J P Galizzi; M Fosset; M Lazdunski
Journal:  Biochem Biophys Res Commun       Date:  1984-01-13       Impact factor: 3.575

9.  Properties of receptors for the Ca2+-channel blocker verapamil in transverse-tubule membranes of skeletal muscle. Stereospecificity, effect of Ca2+ and other inorganic cations, evidence for two categories of sites and effect of nucleoside triphosphates.

Authors:  J P Galizzi; M Fosset; M Lazdunski
Journal:  Eur J Biochem       Date:  1984-10-15

10.  Calcium, sodium, and the calcium paradox.

Authors:  W G Nayler; S E Perry; J S Elz; M J Daly
Journal:  Circ Res       Date:  1984-08       Impact factor: 17.367

View more
  5 in total

Review 1.  The potential for added benefits with beta-blockers and calcium antagonists in treating cardiovascular disorders.

Authors:  W G Nayler
Journal:  Drugs       Date:  1988       Impact factor: 9.546

2.  Interaction of palmitoyl carnitine with calcium antagonists in myocytes.

Authors:  L Patmore; G P Duncan; M Spedding
Journal:  Br J Pharmacol       Date:  1989-06       Impact factor: 8.739

3.  Effect of verapamil withdrawal on cardiac beta 1-adrenoceptor density.

Authors:  W G Nayler; J S Dillon
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Protection by verapamil and nifedipine against ischaemia-induced loss of [3H]-(+)-PN 200-110 binding sites in the rat heart.

Authors:  F T van Amsterdam; M S van Amsterdam-Magnoni; M Haas; N C Punt; J Zaagsma
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990 Jan-Feb       Impact factor: 3.000

5.  The Ca2+ -antagonist and binding properties of the phenylalkylamine, anipamil.

Authors:  J S Dillon; W G Nayler
Journal:  Br J Pharmacol       Date:  1988-05       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.